Catalysts for $REGN

REGENERON PHARMACEUTICALS, INC. earnings

REGENERON PHARMACEUTICALS, INC. earnings

Regeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)

REGENERON PHARMACEUTICALS, INC. earnings

Regeneron Pharmaceuticals Inc — dupilumab (PDUFA)

DUPIXENT (DUPILUMAB) — FDA approval

EYLEA HD (AFLIBERCEPT) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

EYLEA HD (AFLIBERCEPT) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

EVKEEZA (EVINACUMAB-DGNB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

EYLEA HD (AFLIBERCEPT) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

EYLEA HD (AFLIBERCEPT) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

EYLEA HD (AFLIBERCEPT) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval